grepafloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, nalidixic acid derivatives | 1330 | 119914-60-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| CL (Clearance) | 5.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.82 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 9.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 6, 1997 | FDA | OTSUKA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01MA11 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D059005 | Topoisomerase II Inhibitors |
| MeSH PA | D059003 | Topoisomerase Inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Gonorrhea | indication | 15628003 | DOID:7551 |
| Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
| Pneumonia due to Streptococcus | indication | 34020007 | |
| Pneumonia due to Mycoplasma pneumoniae | indication | 46970008 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Urethritis due to Chlamydia trachomatis | indication | 179101003 | |
| Acute Moraxella catarrhalis bronchitis | indication | 195722003 | |
| Acute bacterial bronchitis | indication | 233598009 | |
| Haemophilus Influenzae Bronchitis | indication | ||
| Moraxella Catarrhalis Pneumonia | indication | ||
| Chlamydia Cervicitis | indication | ||
| Streptococcus Pneumoniae Bronchitis | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.14 | acidic |
| pKa2 | 8.66 | Basic |
| pKa3 | 1.49 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.30 | CHEMBL | |||||
| DNA topoisomerase 4 | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| DNA gyrase | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4024097 | VUID |
| N0000022102 | NUI |
| D02178 | KEGG_DRUG |
| 161967-81-3 | SECONDARY_CAS_RN |
| 4021079 | VANDF |
| 4024097 | VANDF |
| C0287721 | UMLSCUI |
| CHEBI:5543 | CHEBI |
| CHEMBL583 | ChEMBL_ID |
| DB00365 | DRUGBANK_ID |
| C075375 | MESH_SUPPLEMENTAL_RECORD_UI |
| 72474 | PUBCHEM_CID |
| 10818 | IUPHAR_LIGAND_ID |
| 7024 | INN_ID |
| L1M1U2HC31 | UNII |
| 236862 | RXNORM |
| 4802 | MMSL |
| d04246 | MMSL |
| 007022 | NDDF |
| 007023 | NDDF |
| 108679003 | SNOMEDCT_US |
| 386892006 | SNOMEDCT_US |
| 719852005 | SNOMEDCT_US |
| CHEMBL1200393 | ChEMBL_ID |
Pharmaceutical products:
None